A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Clinical trial NCT04817007 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04817007
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-22
- Primary completion
- 2028-08-31
- Enrollment
- 216
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.